| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Orticumab
CAS:1314241-10-5
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 |
| Email: |
info@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Orticumab(DHK09901)
CAS:1314241-10-5
Purity:PAGE:>95% Package:100ug;1mg
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:Orticumab
CAS:1314241-10-5
Purity:95% Package:1mg;5mg
|
|
| | Orticumab Basic information |
| Product Name: | Orticumab | | Synonyms: | Orticumab;Research Grade Orticumab(DHK09901);Research Grade Orticumab | | CAS: | 1314241-10-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Orticumab Structure]() |
| | Orticumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Orticumab Usage And Synthesis |
| Uses | Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement[1][2]. | | in vivo | Orticumab (10 mg/mouse; i.p.; once weekly for 3 weeks) reduces atherosclerosis in the aortic arch, decreases the CD68-macrophage subvalvular plaque staining[1].
| Animal Model: | B6.lpr.ApoE-/- mice (18-week-old) fed with high-fat diet (HFD)[1] | | Dosage: | 10 mg/mouse | | Administration: | Intraperitoneal injection; once weekly for 3 weeks | | Result: | Reduced atherosclerosis in the aortic arch by 42.8%, decreased the CD68-macrophage subvalvular plaque staining by 30.5%. |
| | References | [1] Yao Mattisson I, et al. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vascul Pharmacol. 2021 Oct;140:106863. DOI:10.1016/j.vph.2021.106863
[2] Liang BC, et al. Compositions and methods with anti-ApoB100 antibody or fragment for treatment of psoriasis: World Intellectual Property Organization, WO2019232070 A1. 2019-12-05. |
| | Orticumab Preparation Products And Raw materials |
|